BenQ's dialysis overseas arrangement and one-stop strategy have worked well. In 2021, it has achieved outstanding results. The revenue of dialysis business has increased by nearly 80% compared with the same period last year, hitting a new high since the company was established in 2014. At the same time, the BenQ Qflux Dialyzer also has good news to expand overseas markets. In February 2011, it officially obtained the medical license issued by the Ministry of Health of Malaysia, and successfully enter the Malaysian market.

Spark Huang , general manager of BenQ Dialysis, said: "BenQ Dialysis is optimistic about the growth of the domestic and foreign dialysis markets, and actively builds a dialysis product line arrangement, connecting BenQ Biotechnology (Shanghai), K2 International (including Taiwan Headquarters, Shanghai and Thailand Branch), Indonesia Frismed, Golden Spirit Industry and E-Strong Technology, focusing on a full range of hemodialysis solutions, provide one-stop complete products and services. In 2021, the one-stop and chanel arrangement will be effective , the dialysis business performance YoY has grown by nearly 80%, hitting a new high over the years.”

 

Spark Huang further explained: "2021 is a year for the rapid growing of the dialysis business, and there are many gains worldwide. With the continuous improvement of products and processes, the Taiwan market has been highly recognized by the market. Currently, there are more than 260 medical institutions in Taiwan adopt BenQ dialyzer products, and with a penetration rate of more than 30%. China's hemodialysis market continues to accelerate the national channel arrangement, with annual revenue growth of nearly 200%. The ASEAN market is closed due to the epidemic, and business promotion will be slightly affected in 2021. In 2022, it continued to actively deploy channels. Following the Philippines, Thailand, Vietnam and Indonesia, it obtained the Malaysian medical devices license in February, and completed the layout of the five countries in Southeast Asia. The combination of liquid/powder sales coupled with the continued expansion of mainland shipments and the complete layout of the five Southeast Asian countries, it is estimated that the overall performance this year is expected to maintain high growth.”

 

Although the population of Malaysia is only about 30 million, it is the third largest economy among the five countries. In 2018, Malaysia's total medical expenditure was about 14 billion US dollars. According to the USRDS 2018 Annual Report, the incidence of end-stage renal disease patients receiving treatment in Malaysia was 259 PMP (per million), equivalent to nearly 8,000 new cases per year, and the prevalence of dialysis was 1,357 PMP (per million) , the conversion dialysis population is 41,000 people. In addition, Malaysia has the highest rate of diabetic patients in Asia, with one in five adults suffering from diabetes, which shows that the market demand for dialysis equipment and consumables is huge.